Mesenchymal and Pluripotent Stem Cell-Based Strategies for Cardiac Regeneration: Mechanisms, Challenges, and Future Directions.
Lei W., Wang X., Cai J., Pan L.
Narrative Review on Cardiovascular Disease, Immune Modulation, published in Biotechnol J (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Biotechnol J (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41211779
- DOI
- 10.1002/biot.70152
Abstract (original English)
Cardiovascular diseases (CVDs) remain the predominant cause of morbidity and mortality worldwide, with limited curative treatment options for advanced heart failure (HF). While pharmacological and surgical interventions have improved survival, they often fail to regenerate damaged myocardial tissue. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic modality in regenerative medicine, particularly for cardiac repair. This review highlights the role of MSCs in addressing the unmet clinical need for myocardial regeneration, focusing on their biological characteristics, mechanisms of action, and therapeutic applications in various CVDs. MSCs, derived from bone marrow or adipose tissue, exhibit immunomodulatory, anti-fibrotic, and pro-angiogenic properties that facilitate cardiac tissue repair. Their ability to be used in an allogeneic, off-the-shelf format offers practical advantages for large-scale clinical use. However, several challenges, including poor survival post-transplantation, inter-source variability, and complex interactions with the ischemic microenvironment, must be addressed to maximize therapeutic efficacy. Emerging technologies such as gene editing, exosome-based delivery, tissue engineering, and 3D bioprinting offer promising strategies to enhance MSC therapy. This review concludes by outlining future directions for standardization, clinical tra
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev